ライフサイエンスコーパス: pleural mesothelioma

1 therapy for patients with advanced malignant pleural mesothelioma.

2 talc pleurodesis in patients with malignant pleural mesothelioma.

3 ed 68 with advanced ASS1-deficient malignant pleural mesothelioma.

4 os and silica seemed to increase the risk of pleural mesothelioma.

5 e treatment of recurrent and/or unresectable pleural mesothelioma.

6 best available serum biomarker of malignant pleural mesothelioma.

7 rol groups and 1,026 patients with malignant pleural mesothelioma.

8 e of action for asbestos in the induction of pleural mesothelioma.

9 modality therapy in stage I to III malignant pleural mesothelioma.

10 apeutic option in the treatment of malignant pleural mesothelioma.

11 estos and 76 patients with surgically staged pleural mesothelioma.

12 ty in patients with PD-L1-positive malignant pleural mesothelioma.

13 ng of the tumor cells in 36 of 38 samples of pleural mesothelioma.

14 rom those with exposure to asbestos who have pleural mesothelioma.

15 h cisplatin alone in patients with malignant pleural mesothelioma.

16 on in patients with ASS1-deficient malignant pleural mesothelioma.

17 f disease in patients with diffuse malignant pleural mesothelioma.

18 in the palliation of patients with malignant pleural mesothelioma.

19 d were significantly higher in patients with pleural mesothelioma (105+/-7 ng per milliliter in the D

20 s were significantly higher in patients with pleural mesothelioma (694+/-37 ng per milliliter in the

21 Patients with malignant pleural mesothelioma, a rapidly progressing malignancy w

22 investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin le

23 Patients with measurable advanced malignant pleural mesothelioma and disease progression after one o

24 dality therapy in the treatment of malignant pleural mesothelioma and identify prognostic factors.

25 h cisplatin is approved for the treatment of pleural mesothelioma and is active in malignant peritone

26 803 cancer-related genes were studied in 158 pleural mesotheliomas and 18 normal pleura.

27 ins contribute to the malignant phenotype of pleural mesotheliomas and indicate that interventions de

28 has been reported in varying proportions of pleural mesotheliomas and other tumours, but data are co

29 ients with pleural effusion due to malignant pleural mesothelioma, and talc pleurodesis might be pref

30 New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individu

31 The successful treatment of unresectable pleural mesothelioma awaits the discovery of active drug

32 type I IGF receptor in a subset of malignant pleural mesothelioma cell lines and determined the corre

33 ere on the interim analysis of the malignant pleural mesothelioma cohort.

34 results are in favor of an increased risk of pleural mesothelioma for subjects exposed to both asbest

35 409 patients with malignant pleural mesothelioma, from 76 centres in the UK and two

36 d quality of life in patients with malignant pleural mesothelioma have, to our knowledge, not been as

37 ally, the presence of both mutations induced pleural mesotheliomas in 23% of these mice.

38 d Affymetrix U133A microarray analysis on 99 pleural mesotheliomas, in which multivariate analysis sh

39 Malignant pleural mesothelioma incidence continues to rise, with f

40 literature of clinical studies in malignant pleural mesothelioma, including phase II trials of the n

41 Malignant pleural mesothelioma is a highly aggressive cancer with

42 Malignant pleural mesothelioma is a relatively uncommon and yet in

43 Malignant pleural mesothelioma is almost always fatal, and few tre

44 Malignant pleural mesothelioma is an aggressive malignancy charact

45 Malignant pleural mesothelioma is an aggressive primary neoplasm f

46 sed immunotherapy in patients with malignant pleural mesothelioma is feasible, well-tolerated, and ca

47 The incidence of malignant pleural mesothelioma is increasing throughout most of th

48 As pleural mesothelioma is known to have limited numbers of

49 eadily detected in genomic DNA isolated from pleural mesothelioma lines; however, levels of SV40 T/t

50 ishevelled (Dvl) overexpression in malignant pleural mesothelioma (MM).

51 Malignant pleural mesothelioma (MPM) carries a poor prognosis due

52 malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to ben

53 Malignant pleural mesothelioma (MPM) expresses high levels of epid

54 Malignant pleural mesothelioma (MPM) is a deadly disease that occu

55 Malignant pleural mesothelioma (MPM) is a disease of increasing in

56 Malignant pleural mesothelioma (MPM) is a highly aggressive and ge

57 Malignant pleural mesothelioma (MPM) is a highly aggressive tumor

58 Malignant pleural mesothelioma (MPM) is a highly lethal, poorly un

59 Malignant pleural mesothelioma (MPM) is a rare malignancy with no

60 Malignant pleural mesothelioma (MPM) is an aggressive cancer that

61 Malignant pleural mesothelioma (MPM) is an aggressive cancer that

62 Malignant pleural mesothelioma (MPM) is an aggressive human cancer

63 Malignant pleural mesothelioma (MPM) is an aggressive neoplasm ass

64 Malignant pleural mesothelioma (MPM) is an aggressive thoracic can

65 Human malignant pleural mesothelioma (MPM) is considered a rare tumor, b

66 Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an acceptable

67 ed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer

68 targeted exomes (n = 103) from 216 malignant pleural mesothelioma (MPM) tumors.

69 Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) re

70 tor-1 (PAR1, F2R) on the growth of malignant pleural mesothelioma (MPM), using human MPM cells that l

71 therapy as first-line treatment of malignant pleural mesothelioma (MPM).

72 P) in the treatment of epithelioid malignant pleural mesothelioma (MPM).

73 bine have single-agent activity in malignant pleural mesothelioma (MPM).

74 as not been extensively studied in malignant pleural mesothelioma (MPM).

75 ation exclusively in patients with malignant pleural mesothelioma (MPM).

76 rgoing cancer-directed surgery for malignant pleural mesothelioma (MPM); however, it is unclear if th

77 e pathological distinction between malignant pleural mesothelioma (MPM)and adenocarcinoma (ADCA) of t

78 en shown to be highly expressed in malignant pleural mesotheliomas (MPM), was detected in serum using

79 l-cell lung cancer (NSCLC), and 71 malignant pleural mesotheliomas (MPM).

80 ns and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present in control

81 Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 i

82 oncoproteins have been detected in malignant pleural mesotheliomas (MPMs), their role in the pathogen

83 Treatment of human pleural mesothelioma (MS-1) cells with phorbol myristate

84 DNA methylation profiles in a case series of pleural mesotheliomas (n = 23).

85 ria In Solid Tumors (RECIST) version 1.0 for pleural mesothelioma or RECIST version 1.1 for peritonea

86 Ten patients with malignant pleural mesothelioma received metronomic cyclophosphamid

87 ocedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical

88 effective treatments, survival from diffuse pleural mesothelioma remains poor.

89 ur previous microarray analysis of malignant pleural mesothelioma revealed alterations in components

90 ling pathways of the IGF system in malignant pleural mesothelioma specimens.

91 were significantly higher in the group with pleural mesothelioma than in the group with exposure to

92 system components represent novel malignant pleural mesothelioma therapeutic targets for investigati

93 port on their use of a murine model of human pleural mesothelioma to explore potential factors that l

94 benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorin

95 le mechanisms likely contribute to malignant pleural mesothelioma tumorigenesis.

96 (18)F-FDG-CI in the assessment of malignant pleural mesothelioma using histopathology as the gold st

97 Using an orthotopic mouse model of pleural mesothelioma, we determined that relatively high

98 atients with histologically proven malignant pleural mesothelioma were enrolled (26 male patients and

99 eated patients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 centres in si

100 ts (cohort 1, n = 56; cohort 2, n = 52) with pleural mesothelioma were enrolled.

101 ears; 10 women and 29 men) with unresectable pleural mesothelioma were treated with repetitive transa

102 e not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos.

103 spite several attempts at treating malignant pleural mesothelioma with various modalities, mortality

104 Our data suggest that in malignant pleural mesothelioma, Wnt signaling is activated through